Abstracts Archive - Page 1733 of 2425 - ACR Meeting Abstracts

Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld, Bielefeld, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
Abstract Number: 654 • 2015 ACR/ARHP Annual Meeting
Associations Between Skin Outcomes By Body Area Affected and Health-Related Quality of Life in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Alice B. Gottlieb¹, Bengt Hoepken², Luke Peterson³ and Peter C. Taylor⁴, ¹Dermatology, Tufts Medical Center, Boston, MA, ²UCB Pharma, Monheim, Germany, ³UCB Pharma, Raleigh, NC, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) report poorer health-related quality of life (HRQoL) compared to the general population. As with psoriasis (PSO), it is…
Abstract Number: 655 • 2015 ACR/ARHP Annual Meeting
Rasch Analysis of the Hospital Anxiety and Depression Scale in Psoriatic Arthritis: Results from the Presta Study.
Mwidimi Ndosi¹, Ming-Anne Hsu², J. Cappelleri³, Heather Jones⁴, Amit Chhabra⁵ and Philip S. Helliwell⁶, ¹School of Healthcare, University of Leeds, Leeds, United Kingdom, ²445 Eastern Point Road, Pfizer Inc, Groton, CT, ³Statistics, Pfizer Inc, New London, CT, ⁴Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ⁵Pfizer Inc, Collegeville, PA, ⁶Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Hospital Anxiety and Depression Scale (HADs) is a generic measure of psychological status comprising anxiety and depression subscales. The aim of this study…
Abstract Number: 656 • 2015 ACR/ARHP Annual Meeting
Convergent Construct Validity of PsAID12 in a Psoriatic Arthritis Cohort at Baseline
Umut Kalyoncu^1,2, Levent Kilic¹, Abdulsamet Erden¹, Omer Karadag¹, Sule Apras Bilgen¹, Sedat Kiraz¹, Ihsan Ertenli¹, Clifton Bingham³ and Ana-Maria Orbai², ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: The Psoriatic Arthritis Impact of Disease (PsAID) PRO measure was developed for clinical trials (9 item) and routine care (12 item) in Psoriatic arthritis…
Abstract Number: 657 • 2015 ACR/ARHP Annual Meeting
Routine Assessment of Patient Index Data 3 Score (RAPID3) and Psoriasis Quality of Life (PQoL-12) Assess Different Domains in Psoriasis (PsO) and Psoriatic Arthritis (PsA) Patients
Kiana Vakil-Gilani¹, Alexis Dinno², Neha Garg³ and Atul A. Deodhar⁴, ¹Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ²School of Community Health, Portland State University, Portland, OR, ³Rheumatology, Oregon Health and Science University, Portland, OR, ⁴Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR
Background/Purpose: PQoL-12 is a validated composite tool (range: 0–120) assessing patients' quality of life in PsO and PsA. RAPID3 is another validated composite index (range:…
Abstract Number: 658 • 2015 ACR/ARHP Annual Meeting
Health Related Quality of Life in Psoriatic Arthritis from the Perspective of People Living with the Condition
Ana-Maria Orbai^1,2, Suzanne Grieb³, Clifton Bingham⁴, Michelle Jones⁴, Grazyna Purwin⁵ and Katherine Clegg-Smith⁶, ¹Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University, Baltimore, MD, ³Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵Johns Hopkins Arthritis Center, Baltimore, MD, ⁶Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Psoriatic arthritis (PsA) is a complex inflammatory disease with variable phenotype affecting skin, joints, ligaments/tendons, nails, and the spine. Heterogeneity of clinical manifestations complicates…
Abstract Number: 659 • 2015 ACR/ARHP Annual Meeting
Does the Inclusion of Extra-Articular Manifestations Improve Validity of the Self-Administered Comorbidity Questionnaire Modified for Spondyloarthritis (SpA-SCQ)? Results from ASAS-Comospa
Ivette Essers^1,2, Carmen Stolwijk^1,2, Adrien Etcheto³, Anna Molto⁴, Filip van Den Bosch⁵, Désirée van der Heijde⁶, Robert B.M. Landewé^7,8, Astrid van Tubergen^1,2, Maxime Dougados^4,9 and Annelies Boonen^1,10, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Cochin Hospital, Paris Descartes University, Paris, France, ⁴Hopital Cochin, Paris Descartes University, Paris, France, ⁵Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands, Leiden, Netherlands, ⁷Rheumatology, Atrium Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁹Rheumatology Department, Hôpital Cochin, Paris, France, ¹⁰Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: The self-administered comorbidity questionnaire (SCQ) was developed to understand the impact of 13 common comorbidities on functioning and resource utilisation. In patients with ankylosing…
Abstract Number: 660 • 2015 ACR/ARHP Annual Meeting
Comparison of the Four Validated Psoriatic Arthritis Screening Tools in Diagnosing Psoriatic Arthritis in Patients with Psoriasis [Compaq Study]
Aman Sharma¹, Sushant Mishra², Sunil Dogra³ and Harish Kancharla², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Department of Internal Medicine,, PGIMER,, Chandigarh, India, ³Department of Dermatology, PGIMER,, Chandigarh, India
Background/Purpose: Although there are various Psoriatic arthritis (PsA) screening questionnaires, the most optimal screening instrument is not known. The objective of the present study was…
Abstract Number: 661 • 2015 ACR/ARHP Annual Meeting
ASDAS Can be Reliably Calculated When Only the Patient’s Overall Basdai Score Is Available, but Not the Score(S) of Its Individual Component(S)
Pinar Cetin¹, Gokce Kenar¹, Sedat Capar², Handan Yarkan¹, Berrin Zengin¹, Ismail Sari¹, Merih Birlik¹, Fatos Onen¹ and Nurullah Akkoc³, ¹Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ²Dokuz Eylül University Faculty of Statistics, Izmir, Turkey, ³Department of Rheumatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey
Background/Purpose: ASDAS is a composite measure of disease activity for ankylosing spondylitis (AS). Its calculation includes three BASDAI questions, BASDAI Q2 (back pain), Q3 (peripheral…
Abstract Number: 662 • 2015 ACR/ARHP Annual Meeting
Can the New Contest Questionnaire Identify Psoriatic Arthritis in a Primary Care Population?
Laura C Coates, Laura J Savage, Anna R. Moverley and Philip S. Helliwell, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: There is a need for screening questionnaires to identify patients with psoriasis who have undiagnosed psoriatic arthritis but the optimal method is unknown. We…
Abstract Number: 663 • 2015 ACR/ARHP Annual Meeting
Mases Correlates Linearly with Disease Activity and Patient Related Outcomes in Patients with Axial Spondyloarthritis within the Scqm Cohort
Ruediger Mueller¹, Toni Kaegi², Nicole Graf³, Johannes von Kempis⁴ and J.J. Luime⁵, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Kantonsspital St. Gallen, St. Gallen, Switzerland, ³graf biostatistics, Winterthur, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands
Background/Purpose: Enthesitis is one of the potential extra-axial manifestations found in patients with spondyloarthritis (SpA). Enthesitis can be quantified using the MASES (Maastrich Ankylosing Spondylitis…
Abstract Number: 664 • 2015 ACR/ARHP Annual Meeting
Patient Reported Outcomes and Assessment of the Quality of Life in a Cohort of Patients Affected By Enteropathic Spondyloarthritis: Definitive Results of a Monocentric Prospective Observational Study at One Year
Chiara Avellini¹, Laura Bolognini², Alessia Farinelli¹, Monia Ciferri³, Greta Gambacorta³, Devis Benfaremo³, Serena Cedraro³, Matteo Rossini³, William Capeci³, Lucia Manfredi³, Laura Postacchini³, Giammarco Fava², Piergiorgio Mosca², Giovanni Pomponio³, Michele Maria Luchetti³ and Armando Gabrielli³, ¹Scienze Cliniche e Molecolari, Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ²Gastroenterologia, Azienda "Umberto I-G.M.Lancisi-G.Salesi", Ancona, Italy, ³Clinica Medica, Università Politecnica delle Marche, Ancona, Italy
Background/Purpose: Enteropathic spondyloarthritis (ES) are included in the group of the spondyloarthritis (SpA). Because articular involvement is the most frequent extra-intestinal manifestation in patients with…
Abstract Number: 665 • 2015 ACR/ARHP Annual Meeting
Construct Validity of Disease Activity for Psoriatic Arthritis Composite Index and Tentative Cut-Off Values in a Cohort of Patients with Psoriatic Arthritis
Josefina Gallino Yanzi¹, Emilce Schneeberger¹, Osvaldo Luis Cerda¹, Cecilia Zaffarana¹, Margarita Landi¹, Marcos G. Rosemffet², Natalia Zamora³, Tomas Cazenave², Fernando Dal Pra¹, Paula Kohan⁴, Emilio Buschiazzo⁵ and Gustavo Citera², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Hospital Dr. E. Tornu, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Sr Del Milagro, Salta, Argentina
Background/Purpose: Disease Activity for Psoriatic Arthritis (DAPSA) is a composite index that assesses disease activity in patients with Psoriatic Arthritis (PsA) taking into account peripheral…
Abstract Number: 666 • 2015 ACR/ARHP Annual Meeting
Disease Activity Indices and Body Mass Index: Cross-Sectional Analysis of a Large Psoriatic Arthritis Cohort
Umut Kalyoncu¹, Ozun BayndÄ±r¹, Barış Yılmazer¹, Ediz Dalkilic², Kenan Aksu¹, Mustafa Ferhat Oksuz¹, E.Figen Tarhan¹, Meryem Can¹, Orhan Kucuksahin¹, Gezmis Kimyon¹, Lutfi Akyol¹, Ahmet Mesut Onat¹, Bunyamin Kisacik¹, Abdulsamet Erden¹, Ahmet Omma¹, Duygu Ersozlu Bakirli¹, Cem Ozisler¹, Emel Gonullu¹, Seval Pehlevan¹, Dilek Solmaz¹, Muhammet Cinar¹, Gozde Cetin¹, Abdurrahman Tufan¹, Muge Aydin Tufan¹, Levent Kilic¹, Sukran Erten¹, Timucin Kasifoglu¹, Senol Kobak¹, Soner Senel¹, Servet Akar¹, Metin Ozgen¹, Esen Kasapoglu-Gunal¹, Veli Yazisiz¹, Sedat Yılmaz¹, Salim Donmez¹, Ä°smail Dogan¹, Hamide Kart Koseoglu¹, Funda Erbasan¹, Fatih Yildiz¹, Cemal Bes¹, Ayse Balkarli¹, Ali Sahin¹, Rıdvan Mercan¹, Fatoş Arslan¹, Atalay Dogru¹, Salih Pay¹, Sule Yavuz¹, Necati Cakir¹, Yasemin Kabasakal¹ and Sibel Z. Aydin¹, ¹PsART study group, Ankara, Turkey, ²Department of Rhematology, Uludag University Faculty of Medicine, Bursa, Turkey
Background/Purpose: Well known comorbidities of Psoriatic arthritis (PsA) such as cardiovascular disease, metabolic syndrome and diabetes mellitus are closely related with body mass index (BMI).…
Abstract Number: 667 • 2015 ACR/ARHP Annual Meeting
Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Tobee Gunter¹ and Jessica Walsh², ¹Rheumatology, School of Medicine, University of Utah Internal Medicine, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Little is known about how psoriatic arthritis patients and their providers perceive response to therapy. Discrepancies in perceptions of therapy response may indicate that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].